Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

l benefit response (CBR), time to progression (TTP), duration of response (DOR), progression-free survival, and best ORR throughout the study. Patients enrolled in the trial will receive carfilzomib twice weekly for three weeks every 28 days.

"Based on promising laboratory and clinical data, we believe that carfilzomib holds promise in treating patients with multiple myeloma, including those for whom other treatments have failed," said Sundar Jagannath, M.D., Saint Vincent's Comprehensive Cancer Center, where the first patient was enrolled. "We are excited to bring this compound into the MMRC as a critical step in bringing this new treatment to patients."

In the coming weeks, the MMRC and Proteolix will also begin enrolling an open-label, single-arm, Phase 2 study of carfilzomib in patients with relapsed multiple myeloma, who will be stratified by bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) history.

About Carfilzomib

Carfilzomib is a structurally- and mechanistically-novel proteasome inhibitor that exhibits a high level of selectivity for the unique N-terminal threonine active sites within the proteasome. Carfilzomib is similar to bortezomib in that it is a potent inhibitor of the proteasome chymotrypsin- like activity, but unlike bortezomib, carfilzomib has shown minimal cross- reactivity with the other catalytic sites within the proteasome or across other protease classes. Phase 1 clinical studies confirmed that patients who have relapsed or progressed following multiple therapies can still achieve durable anti-tumor responses with carfilzomib. In addition to the two Phase 2 single-agent trials in myeloma and ongoing studies in lymphoma, a clinical trial in solid tumors and a trial exploring carfilzomib in combination with an FDA-approved agent will be initiated by the end of the year.

"The Phase 1 data consistently demonstrate carfilzomib anti-tumor activity in myeloma patients who have failed multiple lines of therapy,
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Alpha Imaging LLC , a leading distributor of advanced medical imaging ... they have been awarded exclusive rights to represent the complete Shimadzu ... territory supplements Alpha Imaging,s existing Shimadzu sales and service responsibilities with ... Indiana , Pennsylvania , ... West Virginia , Delaware and ...
(Date:9/1/2015)... -- Results from an interim analysis of the Phase ... idarucizumab enabled emergency surgery to be initiated rapidly ... (Pradaxa ® dabigatran etexilate mesylate). The specific and ... enabled patients to be urgently brought to necessary ... between administration of idarucizumab and start of procedure. ...
(Date:9/1/2015)... Belgium , Sept. 1, 2015 VolitionRx ... on developing blood-based diagnostic tests for a broad range of ... Executive Officer, Cameron Reynolds , is scheduled to attend ... is being held September 9-10, 2015 in Boston, ... on September 10. Wells Fargo Securities Research ...
Breaking Medicine Technology:Alpha Imaging Expands Shimadzu Territory 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 3VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 4
... Oct. 11 ECRI Institute® ( www.ecri.org ), an ... improving patient care, is pleased to announce Kaiser Permanente ... health plan,  as the winner of the 5th annual ... health technology management. The Health Devices Achievement Award ...
... N.C., Oct. 11 Talecris Biotherapeutics Holdings Corp. (Nasdaq: ... release before the market opens on October 28, 2010. Due ... be hosting a conference call to discuss its third quarter ... Inspiration. Dedication. Innovation. Talecris Biotherapeutics is ...
Cached Medicine Technology:ECRI Institute Names Kaiser Permanente Winner of 5th Annual Health Devices Achievement Award 2ECRI Institute Names Kaiser Permanente Winner of 5th Annual Health Devices Achievement Award 3
(Date:9/1/2015)... Jose, CA (PRWEB) , ... September 01, 2015 ... ... cross-device computing and collaboration, announces Splashtop Business for Remote Support , a ... remote support solution. Unhappy with the escalating renewal prices and inadequate customer ...
(Date:9/1/2015)... Florida (PRWEB) , ... September ... ... of Professional Background Screeners (NAPBS®) has announced that Edge Information Management ... conducted by the Background Screening Credentialing Council (BSCC). , “Achieving and ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... the release of version 5.2 of the FirstSpirit Content Management System with new ... With the new version of FirstSpirit, companies will be well on their way ...
(Date:9/1/2015)... ... 01, 2015 , ... Two of Washington D.C.’s most respected chefs are using ... , Recently named “the next big thing” in the culinary world by Elle ... whole story behind food and reclaiming culinary traditions on the brink of extinction. According ...
(Date:9/1/2015)... York, NY (PRWEB) , ... September 01, 2015 ... ... chosen as the 2015-2016 Distinguished Nurse Scholar-in Residence at the Institute of Medicine ... and Professor of Biomedical Informatics at Columbia University School of Nursing. A member ...
Breaking Medicine News(10 mins):Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:Columbia Nursing’s Suzanne Bakken Named Distinguished Institute of Medicine Nurse Scholar-in-Residence 2
... (GSA) the nation,s largest interdisciplinary organization devoted to ... PhD, of the Chinese University of Hong Kong as ... B. Baltes Foundation Award in Behavioral and Social Gerontology. ... career contributions in behavioral and social gerontology. The ...
... June 24, 2010A unique collaboration among physician-scientists at Memorial ... genomic analysis of prostate cancer to date. "Genomic ... drug targets and strategies to classify patients into clinically ... author Charles Sawyers, Chair of the Human Oncology and ...
... ... award-winning documentary, “Holes in My Shoes.” The film made its broadcast premier last Holiday ... 5, 2010 at 10pm. , ... Tarrytown, NY (Vocus) June 25, 2010 -- ENT and Allergy Associates, LLP (ENTA) is ...
... Ellin Holohan HealthDay Reporter , FRIDAY, June ... chronic migraine headaches feel more rejected, ridiculed, and ostracized ... neurological troubles, a new study contends. And the ... experience, the Philadelphia researchers say. Lead author Dr. ...
... June, 2010 - New research, published by Elsevier in ... Health , provides compelling evidence that deprivation alone cannot ... Although the link between deprivation and health is ... Health (GCPH), along with University of Glasgow, NHS Manchester ...
... Vapure Inc, one ... of American made e-juice. , ... (PRWEB) June 25, 2010 -- Leading electronic cigarette manufacturer Vapure Inc., ... loyal customers, but all electronic cigarette users known as "Vapers" across the U.S.A. , ...
Cached Medicine News:Health News:Fung to receive GSA's 2010 Baltes Foundation Award 2Health News:Large-scale genomic analysis of prostate cancer unveiled 2Health News:ENT and Allergy Associates Sponsors Award Winning PBS Documentary 2Health News:For Migraine Sufferers, Stigma Adds to Burden 2Health News:For Migraine Sufferers, Stigma Adds to Burden 3Health News:Glasgow's high mortality rates are not explained by deprivation alone 2Health News:Leading Electronic Cigarette Manufacturer Vapure Announces U.S. Made E-Liquid 2
Complete Blink-N-Clean lens drops cleans and clears lenses in a blink. It is a unique blend of gentle to the eye ingredients that conveniently cleans, clears and keeps lenses feeling comfortable thro...
... preservative free lubricating and rewetting ... eyes while you're wearing soft ... free formula is ideal for ... to preservatives and for frequent ...
Saline Solution to rinse and store soft contact lenses and for heat disinfection....
Sensitive Eyes Plus Saline Solution to rinse soft contact lenses The unique, gentle, pH-balanced formula contains potassium, an ingredient found in tears....
Medicine Products: